Compass Therapeutics (CMPX) Total Non-Current Liabilities (2019)
Compass Therapeutics (CMPX) posted Total Non-Current Liabilities of $18.6 million for Q4 2019.
Powered by 
Analysis
Compass Therapeutics (CMPX) Total Non-Current Liabilities (2019) Analysis & Trends
Compass Therapeutics has reported Total Non-Current Liabilities for 1 years, with the latest figure at $18.6 million in Q4 2019.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $18.6 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $18.6 million (changed N/A YoY) and the FY2019 annual result came in at $18.6 million, changed N/A from the prior year.
- Total Non-Current Liabilities steadied at $18.6 million in Q4 2019 per CMPX's latest filing.
- Over five years, Total Non-Current Liabilities peaked at $18.6 million in Q4 2019 and troughed at $18.6 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Compass Therapeutics | 442.72 Mn | 442.72 Mn | - | - |